NCT05508620尚未招募1 期
A Phase Ib Study to Evaluate the Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Malignant Solid Tumors With TSC1/2 Genetic Alterations
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.0 个研究点目标入组 270 人开始时间: 2022年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 270
- 主要终点
- Dose-limiting toxicities (DLT)
研究概览
简要总结
This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or TSC2 genetic alterations.
详细描述
This study will be conducted in two stages.
Stage 1: To evaluate the safety, tolerability and pharmacokinetics of Sirolimus for injection (albumin-bound), and determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). The Rolling-six design will be used for dose escalation.
Stage 2: To assess the antitumor activities of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors harboring genetic alterations in TSC1 or TSC2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed diagnosis of malignant solid tumors, with TSC1 or TSC2 genetic alterations, and have no standard treatment or have failed standard treatments.
- •Patients must have archival tumor tissues or agreed to have a tumor biopsy (if not, the sponsor's consent is required for enrollment).
- •At least 1 measurable lesion as defined by RECIST 1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or
- •Life expectancy of ≥3 months.
- •Adequate marrow and organ function.
- •Fasting serum triglyceride must be <300 mg/dL or <3.42 mmol/L; fasting serum cholesterol must be<350 mg/dL or <9.07 mmol/L.
- •Fasting blood glucose must be<6.1 mmol/L and HbA1c< 6.5% in dose escalation, in other stage must be < 7.8 mmol/L and be< 8% respectively.
- •Women of child-bearing potential, or men whose partners are women of childbearing age must agree to use reliable contraceptive methods during the trial period and at least 6 months after the last administration; women of childbearing age must have a negative serum pregnancy test within 7 days prior to the first administration, should not be breast feeding.
- •Patients should understand and willingness to sign a written informed consent form prior to study entry.
排除标准
- •Prior treatment with an mTOR inhibitor.
- •Anti-tumor treatment within 4 weeks prior to first dose of study treatment.
- •Participation in another therapeutic clinical trial with 4 weeks before study treatment.
- •Major surgery within 4 weeks prior to study treatment, or have not fully recovered from any previous procedure.
- •Unresolved toxicity from prior anti-tumor therapy greater than Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.
- •Patients with primary brain tumors or PEComa.
- •Active uncontrolled or symptomatic central nervous system metastasis (CNS) or meningeal metastasis.
- •History of serious cardiovascular disease.
- •History of serious lung disease, such as interstitial lung disease and/or pneumonitis, or pulmonary hypertension, or pre-existing severely impaired lung function.
- •Hydrothorax, ascites or pleural effusion with clinical symptoms or required treatment.
- •Patients with hepatocellular carcinoma (HCC): Child-Pugh class B or C; or HCC with ≥50% liver occupation; or has a history or current evidence of hepatic encephalopathy; portal vein invasion at the main portal branch (Vp4).
- •Live vaccine (including live attenuated vaccine) within 30 days before signing the informed consent.
- •Infection that required systemic anti-infective therapy within 2 weeks before enrollment.
- •History of autoimmune disease or immunodeficiency disease.
- •Active Hepatitis B or Hepatitis C.
- •Use of strong inhibitors or inducers of CYP3A4 within 2 weeks prior to start of treatment initiation, or requiring concomitant treatment during the study.
- •Other server disease that may increase the risk of patients, or interfere the compliance of study procedures, or other reasons which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究组 & 干预措施
Sirolimus for Injection (Albumin-bound)
Experimental
Treatment with Sirolimus for Injection (Albumin-bound) will continue until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
干预措施: Sirolimus for Injection (Albumin-bound) (Drug)
结局指标
主要结局
Dose-limiting toxicities (DLT)
时间窗: At the end of Cycle 1 (each cycle is 21 days)
Overall response rate (ORR)
时间窗: Up to 2 years
Recommended phase 2 dose (RP2D)
时间窗: Up to 2 years
次要结局
- Progression-free Survival (PFS)(Up to 2 years)
- Disease Control Rate (DCR)(Up to 2 years)
- Overall survival (OS)(Up to 2 years)
- Duration of Response (DOR)(Up to 2 years)
- Maximum Plasma Concentration (Cmax)(Up to18 weeks)
- Time to reach maximum plasma concentration (Tmax)(Up to18 weeks)
- Area Under the Curve (AUC)(Up to18 weeks)
研究者
相似试验
已完成
1 期
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)NCT02966782AbbVie70
进行中（未招募）
1 期
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaB-cell Non-Hodgkin LymphomaNCT06251180Guangzhou Lupeng Pharmaceutical Company LTD.112
进行中（未招募）
1 期
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDACMetastatic Pancreatic CancerNCT06059001Peptomyc S.L.26
已完成
1 期
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)Multiple MyelomaNCT02431208Hoffmann-La Roche85
撤回
1 期
JS001+IMP4297 in Patients With Advanced CancerAdvanced CancerNCT05262842Shanghai Junshi Bioscience Co., Ltd.